Generex Biotechnology Announces Plans to Establish

Generex Biotechnology Announces Plans to Establish the NuGenerex Diabetes Research Center in Collaboration With Arizona Endocrinology Group & Paradise Valley Medical Family Medicine
9:00 AM ET, 09/27/2019 - GlobeNewswire
Integrated, collaborative data systems enable population analyticsGenerex plans to accelerate the clinical development of Oral-Lyn-2 for Type-2 diabetes and Altsulin® for Type-1 diabetes
MIRAMAR, Fla., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce plans to establish the NuGenerex Diabetes Research Center in collaboration with Arizona Endocrinology Group and Paradise Valley Family Medicine, P.C., our partners in our previously announced MSO, NuGenerex Health, LLC. Together, the collaborative medical practices provide integrated primary and specialty care, as well as pharmacy services to a patient population of roughly 65,000 patients, 25,000 of whom are insulin-dependent diabetes patients.

The NuGenerex Diabetes Research Center (NDRC) will focus on data analytics and clinical trial management to promote the clinical development of innovative medicines and therapeutic strategies for the benefit of patients. The NuGenerex Health partners utilize a common electronic medical record to facilitate both prospective and retrospective analyses, and with an integrated pharmacy record, enabling virtual clinical research studies that can be used to evaluate compliance and predict outcomes. Also, NDRC plans to evaluate the impact of various educational initiatives to improve patient health.

Another goal of the NDRC will be to accelerate the development of the Generex clinical pipeline, including the reformulated Oral-Lyn-2 for Type-2 diabetes and Altsulin® from our soon to be subsidiary ALTuCELL for the treatment of Type-1 diabetes. Both clinical development programs are expected to initiate in the first quarter of 2020.

Richard Purcell, Generex Executive Vice President of Research and Development said, “By establishing NuGenerex Diabetes Research Center with our partners at Arizona Endocrinology Group and Paradise Valley Family Medicine, we have a platform to relaunch the Oral-Lyn-2 clinical development program and to evaluate the safety and efficacy of ALTuCELL’s amazing microencapsulation technology and cellular implantation therapy that may have the potential to actually cure Type-1 diabetes. Furthermore, we have made a corporate commitment to data analytics, and the opportunities to utilize the real-world real-time, deidentified data sets from a large population of complex diabetes patients will enable us to identify best practices for patient-centric therapy that will improve outcomes and reduce the costs of diabetes care.”

Joe Moscato, President & Chief Executive Officer of Generex commented, “Once we establish the NDRC with our partners, and implement the research platform for our own products, Oral-Lyn-2 and AltsulinÒ, we will open up our diabetes research center of excellence to diabetes drug developers for clinical trials of promising new therapies. It is rare to have a clinical research team with twelve (12) endocrinologists, four (4) internal medicine physicians, and six (6) primary care providers, and a population of about 40,000 patients with diabetes. Plus, we are in discussions with several additional primary care practices with over fifty (50) providers that will provide access to an additional 150,000 patients who may benefit from clinical research opportunities. This powerful NDRC research engine will be very attractive to large pharmaceutical companies with diabetic platforms as we strive to accelerate the development of new medicines.”